SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-063479
Filing Date
2021-03-01
Accepted
2021-03-01 16:17:11
Documents
14
Period of Report
2021-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d125909d8k.htm   iXBRL 8-K 26702
2 EX-99.1 d125909dex991.htm EX-99.1 54893
6 GRAPHIC g125909g85o73.jpg GRAPHIC 5160
  Complete submission text file 0001193125-21-063479.txt   217585

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ccxi-20210301.xsd EX-101.SCH 3080
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ccxi-20210301_lab.xml EX-101.LAB 17372
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ccxi-20210301_pre.xml EX-101.PRE 10959
7 EXTRACTED XBRL INSTANCE DOCUMENT d125909d8k_htm.xml XML 3231
Mailing Address 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Business Address 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043 650-210-2900
ChemoCentryx, Inc. (Filer) CIK: 0001340652 (see all company filings)

IRS No.: 943254365 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35420 | Film No.: 21697973
SIC: 2834 Pharmaceutical Preparations